<DOC>
	<DOCNO>NCT02934919</DOCNO>
	<brief_summary>Impulse control disorder ( ICDs ) ( pathological gambling , hypersexuality , compulsive shopping … ) increasingly recognize psychiatric complication Parkinson 's disease ( PD ) . Therapeutic management disorder important since impact patient quality life . Dopamine agonists play key role emergence ICD . Animal model image underline implication opioid system genesis ICD . An opioid antagonist , naltrexone , study treat ICDs PD . Papay al 2014 find patient treat naltrexone show interesting decrease ICDs measure QUIP RScale . Nevertheless , naltrexone show adverse effect increase hepatic liver enzyme . Nalmefene know hepatic adverse effect . Nalmefene opioid antagonist antagonist action μ δ receptor , also agonist action κ receptor . Grant al 2006 show significant reduction severity pathological gambling patient treat nalmefene . The primary purpose evaluate efficacy safety nalmefene treatment ICDs PD .</brief_summary>
	<brief_title>Evaluation Nalmefene Impulse Control Disorders Parkinson 's Disease : A Prospective Open Label Study</brief_title>
	<detailed_description>In open study , 30 patient ICDs , treat 18 mg per day nalmefene 3 month . Patients evaluate 2 time : inclusion visit ( J0 ) 3 month ( end study , +3months ) . At time , patient : - clinical neurological evaluation - neuropsychological test cognitive , depression TCI evaluation . - blood sample test hepatic renal function - tolerance evaluation list adverse events/effects Patients contact 3 time phone : 2 week inclusion , 1 month inclusion 2 month inclusion , note presence adverse event .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Disruptive , Impulse Control , Conduct Disorders</mesh_term>
	<mesh_term>Nalmefene</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Patient suffer Parkinson 's disease Male Female age 18 80 year old Diagnosis ICDs Ardouin Scale Behavior Parkinson 's Disease ( ASBPD ) score least 2 one Item hyperdopaminergic symptoms No modification treatments PD since 3 month No modification parameter deep brain stimulation since 6 month Patients understood sign consent form Patients social security Contraindication nalmefene ( Patients receive opioid antalgics , antecedent opioid dependence , dopamine agonist withdrawal syndrome , opioid consumption , patient receive methadone buprenorphine , severe hepatic failure , severe renal failure , antecedent alcohol withdrawal , galactose intolerance , lactose deficit glucose malabsorption , pregnant woman ) Cognitive impairment Mini Mental Score &lt; 26 Psychiatric comorbidities ( bipolar disease , schizophrenia ) Patient participate another therapeutic study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Nalmefene</keyword>
	<keyword>Impulse control disorder</keyword>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Tolerance</keyword>
	<keyword>Efficacy</keyword>
</DOC>